Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340685 · ClinicalTrials.gov registry record · Phase 1
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
A Phase 1 study of Pyruvate Dehydrogenase Complex Deficiency, sponsored by Jirair Krikor Bedoyan.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06340685: Recruiting Phase 1 study of Pyruvate Dehydrogenase Complex Deficiency, sponsored by Jirair Krikor Bedoyan.
NCT06340685 is a Phase 1 study of Pyruvate Dehydrogenase Complex Deficiency that is actively recruiting participants, run by Jirair Krikor Bedoyan. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06340685, a Phase 1 study of Pyruvate Dehydrogenase Complex Deficiency, is actively recruiting participants, sponsored by Jirair Krikor Bedoyan.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with PDC Deficiency.
Conditions Studied
Interventions
- DRUG Triheptanoin
Study Locations (1)
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 1 |
What NCT06340685 shows while recruiting
NCT06340685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Pyruvate Dehydrogenase Complex Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Triheptanoin is the first listed.
NCT06340685 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06340685 about?
NCT06340685 is a clinical study titled "Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency". This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that tri...
What is the current status of trial NCT06340685?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-07-11. Estimated completion is 2029-06-30.
What conditions does trial NCT06340685 study?
This clinical trial studies the following conditions: Pyruvate Dehydrogenase Complex Deficiency.
What interventions are being tested in trial NCT06340685?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT06340685?
This trial is sponsored by Jirair Krikor Bedoyan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340685 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pyruvate Dehydrogenase Complex Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06340685's enrollment target sits among peer trials
6 1975th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI